Navigation Links
First biomarker discovered that predicts prostate cancer outcome
Date:8/14/2007

ROCHESTER, Minn. -- Mayo Clinic researchers have identified the first immune molecule that appears to play a role in prostate cancer development and in predicting cancer recurrence and progression after surgery. The report on the B7-H3 molecule by Mayo Clinic Cancer Center appears today in Cancer Research.

This discovery will allow physicians to individualize treatment and observation plans for prostate cancer patients, says Timothy Roth, M.D., a Mayo Clinic urology resident and lead author of the study. Being able to tell a patient his specific risk after surgery, and perhaps even prior to surgery, will be a huge step forward.

Until now there were no strongly-predictive molecules for prostate cancer. The most notable other prostate biomarkers, prostate-specific antigen (PSA), and prostate-specific membrane antigen (PSMA) are useful to diagnose prostate cancer. However, PSA tends to leave prostate cancer cells and migrate throughout the body, making it a poor target for therapy.

Todays Research

In this study, Mayo researchers demonstrate that nearly all normal, pre-malignant and cancerous prostate cells have B7-H3 on their surface. Unlike PSA, B7-H3 stays attached to the surface of prostate cancer cells and does not appear to migrate, thus making B7-H3 a particularly attractive target for therapy. The researchers believe that B7-H3 kills or paralyzes immune cells that are trying to attack the cancer. Their findings indicate that B7-H3 may prove useful as a diagnostic, prognostic and even therapeutic tool because it is stably or increasingly displayed by tumor cells as prostate cancers develop -- even after initiation of anti-hormone therapy, which is the most common treatment for advanced prostate cancer.

The physician-research team examined tissue from 338 consecutive patients who had cancers confined to the prostate and were treated exclusively with a radical prostatectomy (surgery to remove the prostate) between 1995 and 1998. All tumors and precancerous tissues displayed B7-H3, but patients with the highest levels of B7-H3 within their prostate tumors (19.8 percent) were four times more likely to experience cancer progression compared to those with weak levels of B7-H3 within their tumors. Moderate levels of B7-H3 also correlated with a slightly higher risk of recurrence (35 percent).

Because B7-H3 is present in all prostate cancer tumors, and marked levels predict recurrence, we are able to forecast with much greater certainty the likelihood of cancer progression, regardless of therapeutic intervention, says Eugene Kwon, M.D., a senior investigator and urologist at Mayo Clinic.

For some patients, a watchful waiting clinical approach is sometimes used to manage prostate cancer prior to resorting to therapy to see if the cancer becomes increasingly aggressive. The researchers say that the evaluation of B7-H3 levels in prostate biopsies from patients may soon help to determine which patients may benefit from a watchful waiting strategy versus early aggressive treatment.

Individualized Medicine Emerges

Mayo Clinics findings on biomarker identification may accelerate the development of new forms of therapy, say the researchers. Additionally, prostate cancer now joins kidney cancer as a malignancy that can be tracked and predicted based on the presence of B7-H immune molecules.

This is the way of the future, says Dr. Kwon, We are becoming educated about ways to flesh out the molecular signatures of each patients cancer. Using such molecular signatures will facilitate, for the first time, a truly individualized approach to prescribing the most appropriate therapy for a given patient. We will soon be able to tailor-make therapies for each persons cancer.

B7-H3 in the Future

To understand how B7-H3 affects the immune system, and whether a mutation of B7-H3 is involved in the anti-immune activity, more research is necessary. Mayo is planning clinical trials for a number of cancers in late 2008, and researchers are currently developing the necessary therapeutic antibodies to be used in these studies. Investigators expect that clinical laboratory tests for the B7-H proteins may become available at Mayo to assist with the assessment of patients with kidney cancer by late 2007 or early 2008, and then for prostate cancer patients shortly thereafter.

Unique Mayo Registry Key

This study was possible because of Mayos unique patient registry for prostate cancer. The registry contains hundreds of discrete pieces of information, ranging from environmental factors to specific medical test results, for more than 15,000 prostate cancer patients, all followed prospectively since the first patient was entered into the database in 1970. The Mayo Clinic prostate cancer and kidney cancer registries represent the most detailed and complete cancer reference tools in the world. Using the latter registry, Mayo investigators were previously able to link high levels of another B7-H molecule, B7-H1, to poor kidney cancer outcomes, including significantly shortened survival times.

Without the key road maps provided by these registries, the recognition of important molecules that drive cancer would not be feasible, say the researchers. Use of these patient registries enables laboratory science to be directly linked to patient care and survival following treatment.

To a large extent, working with these registries dramatically lessens the time, resources and effort that are required to link a candidate molecule to its role in cancer development and progression, says Dr. Kwon, who is also the co-director of the Cancer Immunology and Immunotherapy Program in Mayo Clinic Cancer Center. Our studies are the very first to provide a clear link between immune molecules and the behaviors of various cancers.

Dr. Kwon and his fellow researchers have been charged by Mayo Clinic to investigate all cancers for immune molecules that may govern cancer behavior while doubling as new therapeutic targets -- identifying future research targets.

Background: B7-H3 and Immunology Research at Mayo

Mayo Clinic Cancer Center was the first to discover the B7-H family of immune molecules -- proteins that normally help regulate the immune response process. Mayo investigators showed that B7-H3 and other members of the B7-H family, such as B7-H1, can have an inhibitory function and actually protect cancers as they develop.

Mayo Clinic identified B7-H3 as a new molecule in 2001. Mayo researchers published the first research identifying an immune molecules role in cancer, with multiple publications pertaining to the role of B7-H1 in heralding a poor prognosis for patients with kidney cancer. Although a number of hypotheses predicted that these molecules might enable cancer development, no one had shown it clinically prior to these studies.

Thus far, the investigators have spent significant time researching the B7-H family of molecules. They have reviewed tens of thousands of samples from at least 30 different cancers, including cancers of the breast, colon, pancreas, brain and ovary, as well as mesothelioma.


'/>"/>

Contact: Elizabeth Zimmermann
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. Infant receives first bloodless liver transplant
3. Oracle Corp. to help build worlds first "Digital Hospital"
4. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
5. First human clone is near
6. First Artificial Heart patient has Major setback
7. First global SARS meet opens
8. Launch Of India’s First Virology Course At Pun
9. FDA approves first pocket-sized EKG machine
10. First head-to-head trials of once weekly Fosamax and Actonel therapies
11. WHO Declares Vietnam First Country to Control SARS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 19, 2017 , ... A July 5th ... weight loss surgery patients who had received a body contouring procedure reported experiencing a ... clinic Beverly Hills Physicians (BHP), which provides both types of procedures, notes that this ...
(Date:7/20/2017)... ... July 20, 2017 , ... “Fidget”: a fun-filled, action-packed ... retired public high school music and drama teacher who was a summa cum laude ... including a “Teacher of the Year” award. After her retirement from public school, Lynn ...
(Date:7/18/2017)... Oaks, CA (PRWEB) , ... July 18, 2017 , ... ... Ph.D. scientist extracted cannabis oils, announced today that at the WORLDZ Summit, taking place ... will be speaking on the therapeutic benefits of medical cannabis for both pediatric and ...
(Date:7/18/2017)... ... July 18, 2017 , ... ClinicalTrials.gov ... Decisions Do You Need to Consider?, **An FDAnews Webinar**, Aug. 2, 2017 — ... Part 11, “Final Rule for Clinical Trials Registration and Results Information,” is a ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... on a lien basis, partners with the best medical professionals who offer the ... and pre-approves each medical professional in their network, ensuring that each patient receives ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Zymo Research Corp., also known as ,The Epigenetics Company, announced ... in a precise manner using the myDNAge ™ test. Based on ... of human genetics and biostatistics at the David Geffen School of ... Zymo Research,s proprietary DNAge ™ technology is used to analyze DNA ... ...
(Date:7/11/2017)...  The global market for liquid biopsy diagnostic and ... in 2016.  Although in early stages, the global market ... as a result of the gradual shift towards personalized ... of a significant number of new liquid biopsy tests ... biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a ... who suffer from painful intercourse and other painful pelvic pain conditions such ... to menopause. ... LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void ...
Breaking Medicine Technology: